Kineta, Inc. Common Stock

Kineta, a clinical-stage biotechnology company, has transitioned from Nasdaq to the OTC Market and is trading under the symbol 'KANT'. The company remains focused on advancing its KVA12123 Phase 1 clinical program and exploring strategic alternatives, including an exclusivity agreement with TuHURA Biosciences.

Related tickers: KA.

Kineta has resumed enrollment for its VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. The trial had been suspended due to funding issues, but Kineta has now secured a $5 million payment from TuHURA Biosciences and is working with them to complete the trial enrollment by the end of 2024.

Related tickers: KA.